Roivant Sciences
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $2,170 | $7,570 | $9,018 | $4,475 |
Gross Profit | 2,016 | 5,982 | 8,759 | 4,241 |
EBITDA | -283,824 | -201,671 | -271,460 | -224,383 |
EBIT | -284,922 | -203,054 | -273,403 | -226,201 |
Net Income | -223,355 | -206,475 | 169,381 | -230,184 |
Net Change In Cash | 2,170 | 7,570 | 9,018 | 4,475 |
Free Cash Flow | -208,418 | -173,376 | -209,078 | -267,802 |
Cash | 1,238,459 | 2,715,411 | 1,990,683 | 1,969,914 |
Basic Shares | 680,286 | 707,299 | 722,716 | 735,471 |
Annual Financials
| Values in thousands | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
Revenue | $29,053 | $124,795 | $61,280 | $55,286 |
Gross Profit | 28,142 | 96,831 | 48,152 | 46,320 |
EBITDA | -674,258 | 4,310,244 | -1,178,009 | -916,706 |
EBIT | -681,590 | 4,288,208 | -1,196,866 | -922,638 |
Net Income | -171,981 | 4,348,926 | -1,009,030 | -845,262 |
Net Change In Cash | 29,053 | 124,795 | 61,280 | 55,286 |
Cost of Revenue | -388,200 | -67,642 | ||
Free Cash Flow | -844,050 | -766,650 | -856,083 | -695,165 |
Cash | 2,715,411 | 6,535,706 | 1,676,813 | 2,060,400 |
Basic Shares | 725,396 | 831,049 | 712,791 | 669,753 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.25 |
2025-03-31 | -$0.29 |
2024-12-31 | -$0.19 |
